PQUS0.880%
as of Sep 1
BMY
GrowthBRISTOL-MYERS SQUIBB COMPANY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom.
Close · 3M
+15.65%
Held by 1 AI ETF
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals20
Win rate95% (19/20)
Avg buy return+11.74%
PQUS · Weight increase · 3d
weight 0.810% → 0.890% (+0.080 pp)·stock up 2.7% in the 30 days before
Aug 28·entry $66.58·now $66.82Fresh
+0.36%
since Aug 28
PQUS · Weight increase · 2d
weight 0.810% → 0.830% (+0.020 pp)·stock up 6.1% in the 30 days before
Aug 27·entry $66.95·now $66.82Fresh
-0.19%
since Aug 27
PQUS · Weight increase · 2d
weight 0.790% → 0.820% (+0.030 pp)·stock up 7.8% in the 30 days before
Aug 20·entry $65.47·now $66.82Drifting
+2.06%
since Aug 20
PQUS · Weight increase · 2d
weight 0.750% → 0.780% (+0.030 pp)·stock up 8.6% in the 30 days before
Jul 19·entry $60.16·now $66.82Chased
+11.07%
since Jul 19
PQUS · Accumulation · 5d
weight 0.710% → 0.810% (+0.100 pp)·stock up 2.7% in the 30 days before
Jul 1·entry $56.44·now $66.82Chased
+18.39%
since Jul 1
PQUS · Accumulation · 5d
weight 0.700% → 0.800% (+0.100 pp)·stock up 0.8% in the 30 days before
Jun 30·entry $57.62·now $66.82Chased
+15.97%
since Jun 30
PQUS · Accumulation · 5d
weight 0.700% → 0.800% (+0.100 pp)·stock up 2.9% in the 30 days before
Jun 29·entry $58.56·now $66.82Chased
+14.11%
since Jun 29
PQUS · Accumulation · 5d
weight 0.700% → 0.800% (+0.100 pp)·stock down 0.0% in the 30 days before
Jun 28·entry $58.56·now $66.82Chased
+14.11%
since Jun 28
PQUS · Weight increase · 4d
weight 0.700% → 0.770% (+0.070 pp)·stock down 0.0% in the 30 days before
Jun 27·entry $58.56·now $66.82Chased
+14.11%
since Jun 27
PQUS · Weight increase · 3d
weight 0.700% → 0.760% (+0.060 pp)·stock down 0.0% in the 30 days before
Jun 26·entry $57.52·now $66.82Chased
+16.17%
since Jun 26
PQUS · Weight increase · 2d
weight 0.700% → 0.730% (+0.030 pp)·stock down 4.5% in the 30 days before
Jun 25·entry $55.39·now $66.82Chased
+20.64%
since Jun 25
PQUS · Weight increase · 2d
weight 0.580% → 0.740% (+0.160 pp)·stock up 1.3% in the 30 days before
Jun 12·entry $57.13·now $66.82Chased
+16.96%
since Jun 12
+20.24%
since Jun 7
+16.86%
since May 29
PQUS · Weight increase · 2d
stock down 3.3% in the 30 days before
May 17·entry $57.31·now $66.82Chased
+16.59%
since May 17
LQAI · Exit · 1d
weight 0.440% → 0 (exited)·stock up 11.5% in the 30 days before
Aug 6·entry $64.15·now $66.82
+4.16%
since Aug 6
LQAI · Weight increase · 4d
weight 0.400% → 0.440% (+0.040 pp)·stock up 7.8% in the 30 days before
Jul 29·entry $63.10·now $66.82Drifting
+5.90%
since Jul 29
LQAI · Weight increase · 3d
weight 0.400% → 0.430% (+0.030 pp)·stock up 10.6% in the 30 days before
Jul 28·entry $63.60·now $66.82Drifting
+5.06%
since Jul 28
LQAI · Weight increase · 2d
weight 0.400% → 0.420% (+0.020 pp)·stock up 12.9% in the 30 days before
Jul 24·entry $62.09·now $66.82Drifting
+7.62%
since Jul 24
LQAI · Weight increase · 3d
weight 0.370% → 0.410% (+0.040 pp)·stock up 8.6% in the 30 days before
Jul 17·entry $60.74·now $66.82Chased
+10.01%
since Jul 17
LQAI · Weight increase · 2d
weight 0.370% → 0.400% (+0.030 pp)·stock up 7.6% in the 30 days before
Jul 16·entry $60.51·now $66.82Chased
+10.43%
since Jul 16
LQAI · New entry · 1d
weight 0 → 0.380% (new)·stock up 2.4% in the 30 days before
Jul 7·entry $57.97·now $66.82Chased
+15.27%
since Jul 7
LQAI · Exit · 1d
weight 0.160% → 0 (exited)·stock up 0.6% in the 30 days before
Jun 9·entry $56.48·now $66.82
+18.31%
since Jun 9
+18.37%
since May 12
+20.03%
since May 11
+18.08%
since May 6
+17.33%
since May 5
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Too hard to callas of Jun 28
The AI ETFs, particularly PQUS, show a pattern of gradual accumulation in Bristol-Myers Squibb, indicating their algorithms identify a buying opportunity or positive trend. This contrasts sharply with a Buffett-style framework, which deems the company too unpredictable for reliable long-term valuation due to patent expirations and R&D challenges.
- Circle of CompetenceThe pharmaceutical industry's reliance on successful R&D and the finite lifecycle of patents make reliable ten-year cash flow projections challenging, particularly with upcoming patent expirations for key drugs.
- Economic MoatAn assessment of economic moats is not undertaken as the business falls outside the circle of competence for reliable long-term projections.
- ManagementManagement quality cannot be assessed within this framework once the business is deemed too complex for long-term predictability.
- Financial HealthKey financial metrics are not evaluated when the foundational predictability of earnings is absent.
- Margin of SafetyWithout predictable cash flows, a conservative estimate of intrinsic value for a margin of safety cannot be established.
Bristol-Myers Squibb is deemed 'Too Hard' to evaluate within a Buffett-style framework due to the inherent unpredictability of long-term cash flows in the pharmaceutical industry. The challenges of patent cliffs and the uncertain success of R&D make reliable ten-year projections difficult. Consequently, further analysis of its moat, management, financial health, or margin of safety cannot be confidently conducted.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.